Healius’ unaudited first half results missed market forecasts, following a drop in half-year earnings thanks to a collapse in mass COVID-19 testing.
The healthcare company reported first half earnings before interest, tax, depreciation and amortisation dropped 64 per cent to $182 million in the six months to December 31, below consensus expectations for $196 million.“The drivers of diagnostic testing remain strong and Healius expects reversion to long-term growth trends,” the company said in a statement.
“We expect consensus to remain cautious on the second half of 2023 outlook given the miss to both revenue and earnings in the first half,” said RBC analyst Craig Wong-Pan in a note.